STOCK TITAN

Allogene Therapeutics Stock Price, News & Analysis

ALLO Nasdaq

Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.

Allogene Therapeutics, Inc. (ALLO) is a clinical-stage biotechnology leader developing off-the-shelf CAR T cell therapies for cancer and autoimmune diseases. This news hub provides investors and industry professionals with timely updates on clinical advancements, regulatory milestones, and strategic partnerships shaping the future of allogeneic cell treatments.

Access authoritative updates on ALLO's innovative pipeline, including progress with Dagger® technology and CRISPR-engineered therapies. Our curated news collection offers:

- Press releases detailing trial results and FDA interactions
- Financial reports and earnings call summaries
- Analysis of collaborations with academic and industry partners
- Updates on manufacturing scalability and therapeutic applications

Bookmark this page for centralized access to verified information on Allogene's progress in creating accessible, next-generation cell therapies. Check regularly for developments in hematologic malignancies, solid tumor treatments, and autoimmune disease research.

Rhea-AI Summary

Allogene Therapeutics presented positive Phase 1 TRAVERSE trial data for ALLO-316 in treating advanced renal cell carcinoma (RCC). The trial showed a 50% overall response rate and 33% confirmed response rate in patients with CD70 Tumor Proportion Score ≥50%. Among 39 enrolled patients, 26 were CD70 positive and evaluable for efficacy. The treatment demonstrated a manageable safety profile, with cytokine release syndrome being the most common adverse event. The FDA granted RMAT designation to ALLO-316 for advanced or metastatic RCC treatment. Additional data from the Phase 1b expansion cohort is expected in mid-2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary

Allogene Therapeutics will present new data from its Phase 1 TRAVERSE trial for ALLO-316, an off-the-shelf AlloCAR T™ therapy targeting CD70-positive renal cell carcinoma (RCC), at the International Kidney Cancer Symposium and SITC Annual Meeting. The presentations will showcase data from 26 heavily pretreated patients and include details on managing treatment-associated hyperinflammatory responses.

The FDA granted RMAT designation to ALLO-316 in October 2024, recognizing its potential to address unmet needs in adult patients with advanced RCC who have failed standard therapies. The ongoing TRAVERSE trial demonstrates ALLO-316's ability to elicit responses from a single infusion, suggesting a breakthrough in allogeneic CAR T therapy for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
-
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T products for cancer and autoimmune disease, has announced its participation in two major investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 18 at 5:35AM PT and the Jefferies London Healthcare Conference on November 20 at 10:00AM GMT. Webcasts will be available on the company's website for approximately 30 days after the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
none
Rhea-AI Summary

Allogene Therapeutics (ALLO), a clinical-stage biotech company focused on allogeneic CAR T products, will release its Q3 2024 financial results on November 7, 2024, after market close. The company will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET on the same day. Interested parties can access the webcast through the company's website, with a replay available for approximately 30 days. Those wishing to ask questions during the call must register to receive a personal PIN for access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
conferences earnings
-
Rhea-AI Summary

Allogene Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-316 for treating adult patients with CD70 positive advanced or metastatic renal cell carcinoma (RCC). The designation was based on clinical data from the TRAVERSE trial, showing potential in treating patients who failed multiple standard RCC therapies. ALLO-316 utilizes the Dagger® technology as a next-generation allogeneic platform for single-infusion 'off-the-shelf' CAR T therapy. The company will present updated Phase 1 data at the upcoming SITC annual meeting. ALLO-316 previously received Fast Track Designation in March 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
-
Rhea-AI Summary

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, has announced its participation in the Goldman Sachs Cell Therapy Day Conference. The event is scheduled for October 1, 2024 in New York.

Allogene will be part of a panel discussion centered on innovations in the allogeneic cell therapy landscape. The panel is set to take place at 10:00 AM PT/1:00 PM ET. A webcast of the discussion will be available on the company's website at www.allogene.com under the Investors tab in the News and Events section. The replay will remain accessible for approximately 30 days after the live webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
none
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) will present pre-clinical data for ALLO-329, its next-generation investigational AlloCAR T candidate for autoimmune indications, at the ACR Convergence 2024. ALLO-329 is a CD19/CD70 dual AlloCAR T product designed to target both B-cells and T-cells implicated in autoimmune diseases. It utilizes CRISPR-based site-specific integration and incorporates the Dagger® technology to potentially reduce or eliminate the need for lymphodepletion.

The company aims to address challenges in CAR T therapy for autoimmune diseases by making it available off-the-shelf and potentially reducing chemotherapy conditioning. Allogene plans to file an IND application in Q1 2025 and expects proof-of-concept by year-end 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
conferences clinical trial
-
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases, has announced its participation in two upcoming investor conferences:

1. Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 7:00 AM PT/10:00 AM ET

2. Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024, at 7:15 AM PT/10:15 AM ET

Webcasts, if available, will be accessible on the company's website at www.allogene.com under the Investors tab in the News and Events section. Replays will be available for approximately 30 days after the live webcasts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
conferences
-
Rhea-AI Summary

Allogene Therapeutics reported Q2 2024 financial results and provided business updates. Key highlights include:

1. Initiation of pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL consolidation, with enrollment completion expected in 1H 2026 and potential BLA submission in 2027.

2. ALLO-329 IND application for autoimmune diseases on track for Q1 2025, with proof-of-concept data expected by YE 2025.

3. ALLO-316 Phase 1 TRAVERSE data update in RCC planned for YE 2024.

4. Q2 2024 ended with $444.6M in cash, cash equivalents, and investments, with runway projected into 2H 2026.

5. Q2 2024 net loss of $66.4M, or $0.35 per share.

6. 2024 guidance unchanged, expecting a decrease in cash of ~$200M and GAAP Operating Expenses of ~$300M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases, has announced its plans to report second quarter 2024 financial results and provide a business update. The company will host a conference call and webcast on August 7, 2024, at 2:00 p.m. PT/5:00 p.m. ET, following the market close.

Investors and interested parties can access the listen-only webcast on Allogene's website under the Investors tab in the News and Events section. A replay will be available for approximately 30 days. Those wishing to participate in the Q&A session during the conference call must register separately to receive a personal PIN for access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences earnings

FAQ

What is the current stock price of Allogene Therapeutics (ALLO)?

The current stock price of Allogene Therapeutics (ALLO) is $1.19 as of July 3, 2025.

What is the market cap of Allogene Therapeutics (ALLO)?

The market cap of Allogene Therapeutics (ALLO) is approximately 262.5M.
Allogene Therapeutics

Nasdaq:ALLO

ALLO Rankings

ALLO Stock Data

262.48M
148.74M
17.73%
77.84%
18.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO